2014 - Canadian Medical Hall of Fame
Fellow of the American College of Cardiology (ACC)
Salim Yusuf mainly investigates Internal medicine, Cardiology, Myocardial infarction, Surgery and Stroke. Many of his studies on Internal medicine involve topics that are commonly interrelated, such as Diabetes mellitus. His Cardiology course of study focuses on Ramipril and Telmisartan.
His Myocardial infarction research is multidisciplinary, incorporating elements of Perioperative and Confidence interval. His Surgery study integrates concerns from other disciplines, such as Angiotensin II, Placebo and Risk factor. In his study, which falls under the umbrella issue of Stroke, Bradycardia is strongly linked to Atrial fibrillation.
Salim Yusuf mainly focuses on Internal medicine, Cardiology, Myocardial infarction, Stroke and Surgery. His study looks at the relationship between Internal medicine and fields such as Diabetes mellitus, as well as how they intersect with chemical problems. In the subject of general Cardiology, his work in Ejection fraction is often linked to In patient, thereby combining diverse domains of study.
His research in Myocardial infarction intersects with topics in Odds ratio, Placebo and Coronary artery disease. The concepts of his Stroke study are interwoven with issues in Aspirin and Epidemiology. Salim Yusuf has included themes like Anesthesia and Clinical trial in his Randomized controlled trial study.
His primary areas of investigation include Internal medicine, Stroke, Cardiology, Myocardial infarction and Disease. His work in Aspirin, Hazard ratio, Atrial fibrillation, Heart failure and Randomized controlled trial are all subfields of Internal medicine research. The various areas that Salim Yusuf examines in his Stroke study include Clinical trial, Statin, Blood pressure, Developing country and Cardiac surgery.
His Cardiology study incorporates themes from Diabetes mellitus, Framingham Risk Score and Montreal Cognitive Assessment. His studies deal with areas such as Regimen and Anesthesia as well as Myocardial infarction. His work carried out in the field of Disease brings together such families of science as Prospective cohort study, Epidemiology, Health care and Risk factor.
The scientist’s investigation covers issues in Internal medicine, Stroke, Cardiology, Hazard ratio and Myocardial infarction. His Internal medicine and Aspirin, Randomized controlled trial, Heart failure, Coronary artery disease and Atrial fibrillation investigations all form part of his Internal medicine research activities. Salim Yusuf interconnects Genetics, Clinical trial, Family medicine, Dabigatran and Evidence-based medicine in the investigation of issues within Stroke.
His work on Revised Cardiac Risk Index as part of his general Cardiology study is frequently connected to In patient, thereby bridging the divide between different branches of science. His Hazard ratio research incorporates themes from Randomization, Prospective cohort study, Proportional hazards model and Cohort study. His work deals with themes such as Regimen, Placebo and Risk assessment, which intersect with Myocardial infarction.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary
The Lancet (2002)
Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.
Solvd Investigators;Salim Yusuf;Bertram Pitt;Clarence E Davis.
The New England Journal of Medicine (1991)
COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS
R Altman;L Carreras;R Diaz;E Figueroa.
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial
John Jv McMurray;Jan Östergren;Karl Swedberg;Christopher B Granger.
The Lancet (2003)
ACC/AHA Guidelines for Coronary Artery Bypass Graft Surgery A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1991 Guidelines for Coronary Artery Bypass Graft Surgery)
Kim A. Eagle;Robert A. Guyton;Ravin Davidoff;Gordon A. Ewy.
Journal of the American College of Cardiology (1999)
Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.
Jfe Mann;HC Gerstein;S Yusuf.
The Lancet (2000)
Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation
Stuart J. Connolly;Janice Pogue;Robert G. Hart;Stefan H. Hohnloser.
The New England Journal of Medicine (2009)
The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years.
M Coutinho;H C Gerstein;Y Wang;S Yusuf.
Diabetes Care (1999)
Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme
Marc A Pfeffer;Karl Swedberg;Christopher B Granger;Peter Held.
The Lancet (2003)
ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group.
R Collins;R Peto;M Flather;S Parish.
The Lancet (1995)
Profile was last updated on December 6th, 2021.
Research.com Ranking is based on data retrieved from the Microsoft Academic Graph (MAG).
The ranking h-index is inferred from publications deemed to belong to the considered discipline.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: